Navigation Links
PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals

LONDON and CAMBRIDGE, England, July 26, 2013 /PRNewswire/ --

PolyTherics receives new investment to accelerate growth

PolyTherics Limited ("PolyTherics") announces that it has merged with Antitope Limited ("Antitope"), the leading provider of antibody engineering and immunogenicity screening services, to create an enlarged group with an extensive suite of services and technologies to enable the development of better biopharmaceuticals.

PolyTherics is issuing new shares up to an aggregate value of £13.5 million to fund the merger with Antitope and to provide working capital for the enlarged group. Imperial Innovations (AIM: IVO) led the investment and brought in new investor Invesco Perpetual with further funds provided by Mercia Fund Management and Advantage Enterprise & Innovation Fund.

The enlarged PolyTherics group will leverage its combined portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. The combined portfolio will include conjugation technologies to produce more stable and homogeneous antibody drug conjugates, technologies to optimise the pharmacokinetics of biologics, technologies for immunogenicity screening, technologies to re-engineer antibodies and proteins to reduce their immunogenicity, and cell line development technologies. The group has a strong client base in the biotechnology and pharmaceutical industry, including many of the world's top companies.

Dr John Burt will continue as CEO of PolyTherics and Antitope will operate as a wholly owned subsidiary of the PolyTherics group. Dr Matthew Baker will continue as Chief Scientific Officer for Antitope and the company will retain its base, management and operational structure at the Babraham Research Campus, near Cambridge.    

The expanded offering will provide the PolyTherics group with a broad technology platform for growth and a solid financial base with sustainable revenue streams over the short-, medium- and longer-term. Growing revenues are derived from the services offered by Antitope and feasibility studies undertaken by PolyTherics and from pre-defined milestone payments under licence agreements for the group's conjugation and de-immunisation technologies. These licences also have the potential to provide future royalties on a portfolio of products which utilise the group's proprietary technologies.

Dr John Burt, CEO of PolyTherics, said: "The combination of PolyTherics and Antitope is a significant strategic step, immediately broadening our business and accelerating our growth. We look forward to building PolyTherics into a leading global provider of technologies that enable the development of better biopharmaceuticals."

Dr Matthew Baker, CEO and CSO of Antitope, said: "The combination of Antitope with PolyTherics provides an excellent opportunity for us to expand and grow our offering to our existing partners. The combined company will have critical mass in terms of technologies, skills and resources and will enable us to leverage the full potential of our antibody engineering and deimmunisation platforms. We are delighted to become part of the PolyTherics group and believe this move will enable us to support growing demand for our technologies from the global biopharma industry."

About PolyTherics

PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development.

PolyTherics' portfolio includes proprietary site-specific conjugation technologies and novel polymers for optimising the therapeutic properties of biopharmaceuticals, including ThioBridge™ for more stable and homogeneous antibody drug conjugates, TheraPEG™, CyPEG™, HiPEG™ and PolyPEG™ for optimisation of the pharmacokinetics of biologics  and GlycoPol™ for targeted delivery.

The PolyTherics group will provide immunogenicity testing, antibody humanisation and protein re-engineering technologies through its Antitope subsidiary, including EpiScreen™, Composite Human Antibody™, Composite Protein™ and Composite CHO™. These technologies have been used to develop several therapeutic antibody candidates that are advancing through clinical trials. The group provides its services and technologies to an international client base that includes many of the world's leading biotechnology and pharmaceutical companies.

PolyTherics is a privately owned UK company backed by institutional investors including Imperial Innovations (AIM: IVO), Invesco Perpetual, Mercia Fund Management, Advantage Enterprise & Innovation Fund (managed by Catapult Venture Partners), ProVen Health, Oxford Technology VCTs and high net worth individual's funds managed by Longbow Capital. The Company has dedicated facilities in London, Cambridge and Coventry, UK.

For more information contact:

John Burt, PolyTherics
Tel.: +44(0)20-7691-3580

Matthew Baker, Antitope
Tel.: +44(0)1223-496190

Mark Swallow, Sita Shah, Chris Gardner
Citigate Dewe Rogerson
Tel.: +44(0)20-7282-2948/1052/2995

SOURCE PolyTherics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shimadzu's New MALDI-7090 TOF-TOF Mass Spectrometer Combines High Throughput, High Resolution and High Energy for the Ultimate in Tandem MS Capabilities
2. FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice
3. Fantastic flash memory combines graphene and molybdenite
4. Motus Brings a Whole New Dimension to the NFL Combine Training Program at IMG Academy
5. New Informatics and Bioimaging Center combines resources, expertise from UMD, UMB
6. GDS International Combines Top Healthcare Executives in the United States for its 10th Anniversary NG Healthcare Summit in May
7. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
8. NYSCF scientists create personalized bone substitutes from skin cells
9. American Management Association Teams With Biogen Idec To Create Life Skills Workshops For People Living With Hemophilia
10. Data Spectacles Create Rosy Tint
11. Leading Biotoxin & Mold Illness Authority Creates Certification Process for Treatment Protocol
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... This fall, global software solutions leader SAP and AdVenture ... develop and pitch their BIG ideas to improve health and wellness in their schools. ... to win the title of SAP's Teen Innovator, an all-expenses paid trip to Super ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of ... has promoted Melanie Aregger to serve as Chief Operating Officer. , Having ... management team and was promoted to Head of InSphero Diagnostics in 2014. ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
Breaking Biology Technology:
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
Breaking Biology News(10 mins):